UNITY Biotechnology, Inc. (UBX, Financial) has announced promising findings from a study published in the journal NEJM Evidence regarding its UBX1325 treatment for patients with diabetic macular edema (DME). The Phase 2 BEHOLD study centered on the effects of selectively targeting senescent cells in the retina.
The results of the study indicate that UBX1325 may offer significant, disease-modifying benefits, and provide long-lasting improvements in vision for those suffering from DME. These findings highlight the potential for UBX1325 to emerge as an innovative treatment option in the fight against retinal diseases.
